|Chemical and physical data|
|Molar mass||958.34 g·mol−1|
|3D model (JSmol)|
Lenacapavir (development code GS-6207) is an experimental drug for the treatment of HIV being developed by Gilead Sciences. As of 2021, it is in Phase 2/3 clinical trials. It is being investigated as a treatment for HIV patients infected with multidrug-resistant virus and as a twice-yearly injectable for pre-exposure prophylaxis (PrEP).
- Link JO, Rhee MS, Tse WC, Zheng J, Somoza JR, Rowe W, et al. (August 2020). "Clinical targeting of HIV capsid protein with a long-acting small molecule". Nature. 584 (7822): 614–618. Bibcode:2020Natur.584..614L. doi:10.1038/s41586-020-2443-1. PMC 8188729. PMID 32612233. S2CID 220293679.
- Boerner H (11 March 2021). "Lenacapavir Effective in Multidrug Resistant HIV". Medscape.
- Highleyman L (15 March 2021). "Lenacapavir Shows Promise for Long-Acting HIV Treatment and Prevention". POZ.
- Gallagher GM (12 March 2020). "Trial Data Released for Investigational HIV-1 Capsid Inhibitor". Contagion Live.